3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Glioma
6
Glioblastoma
5
Gliosarcoma
4
Brain Neoplasms
4
Neoplasms
2
Disease Progression
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Astrocytoma
1
Adenocarcinoma, Follicular
1
Interventions
3-Iodobenzylguanidine
8
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
5
Temozolomide
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
anlotinib
3
Everolimus
3
olaparib
2
cabozantinib
2
belzutifan
2
Sunitinib
2
Phenoxybenzamine
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraganglioma
×
vandetanib
×
CNS
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn